Adenovirus News and Research RSS Feed - Adenovirus News and Research

Adenoviruses most commonly cause respiratory illness; however, depending on the infecting serotype, they may also cause various other illnesses, such as gastroenteritis, conjunctivitis, cystitis, and rash illness. Symptoms of respiratory illness caused by adenovirus infection range from the common cold syndrome to pneumonia, croup, and bronchitis. Patients with compromised immune systems are especially susceptible to severe complications of adenovirus infection. Acute respiratory disease (ARD), first recognized among military recruits during World War II, can be caused by adenovirus infections during conditions of crowding and stress.
DNAtrix signs agreement to utilize Alcyone's MEMS platform for direct drug delivery into glioblastoma

DNAtrix signs agreement to utilize Alcyone's MEMS platform for direct drug delivery into glioblastoma

Alcyone Lifesciences, Inc., a leader in neural intervention systems for neurological conditions and targeted drug delivery, and DNAtrix Inc., a privately held biotechnology company and a leader in oncolytic virus therapy, have entered into an exclusive clinical collaboration. Under the agreement, DNAtrix will utilize Alcyone's MEMS Cannula (AMC) targeted delivery platform for the intratumoral delivery of DNX-2401, an oncolytic adenovirus and DNAtrix's lead product for the treatment of the most aggressive form of brain cancer, glioblastoma (GBM). [More]
Experimental gene therapy holds promise against metastatic prostate cancer

Experimental gene therapy holds promise against metastatic prostate cancer

Even with the best available treatments, the median survival of patients with metastatic, hormone-refractory prostate cancer is only two to three years. Driven by the need for more effective therapies for these patients, researchers at VCU Massey Cancer Center and the VCU Institute of Molecular Medicine have developed a unique approach that uses microscopic gas bubbles to deliver directly to the cancer a viral gene therapy in combination with an experimental drug that targets a specific gene driving the cancer's growth. [More]
T cell expansion technology: an interview with Alexander Malykhin, CVPF, University of Pennsylvania

T cell expansion technology: an interview with Alexander Malykhin, CVPF, University of Pennsylvania

T cells are taken from the patient’s blood and then modified using lentivirus, adenovirus or RNA electroporation. The modifications allow us to reprogram T cells to recognize cancer cells. [More]
Ebola survivors face long-term adverse health effects: Study

Ebola survivors face long-term adverse health effects: Study

Ebola survivors experienced negative health effects that persisted more than two years after the 2007-2008 Bundibugyo ebolavirus (BDBV) outbreak in Uganda that claimed 39 lives. These findings are detailed in a paper published online today in Lancet ID. [More]
GenVec, Laboratory of Malaria Immunology and Vaccinology sign research collaboration agreement

GenVec, Laboratory of Malaria Immunology and Vaccinology sign research collaboration agreement

GenVec, Inc. today announced that it has signed a research collaboration agreement with the Laboratory of Malaria Immunology and Vaccinology of the National Institute of Allergy and Infectious Diseases, National Institutes of Health. [More]
New Ebola vaccine shows promise in first phase 1 clinical trial

New Ebola vaccine shows promise in first phase 1 clinical trial

Results from the first phase 1 trial of an Ebola vaccine based on the current (2014) strain of the virus are today published in The Lancet. Until now, all tested Ebola virus vaccines have been based on the virus strain from the Zaire outbreak in 1976. The results suggest that the new vaccine is safe, and provokes an immune response in recipients, although further long-term testing will be needed to establish whether it can protect against the Ebola virus. [More]
Personalized gene therapy to fight against cancer

Personalized gene therapy to fight against cancer

The fight to treat cancer and eradicate tumors will likely benefit from a new set of treatments if early development phases continue to show promise, according to Kalorama Information. The healthcare market research publisher stated that gene therapies that are able to deliver genetic material to a specific cell population or tumor that will result in the destruction of the tumor. [More]
GenVec collaborates with TheraBiologics to develop NSC-mediated cancer therapeutics

GenVec collaborates with TheraBiologics to develop NSC-mediated cancer therapeutics

GenVec, Inc. today announced that it has formed a collaboration with TheraBiologics to develop cancer therapeutics leveraging both GenVec's proprietary gene delivery platform and TheraBiologics' proprietary neural stem cell (NSC) technology. [More]
Study reveals causes of community-acquired pneumonia in children

Study reveals causes of community-acquired pneumonia in children

With the chill of winter comes a spike in community-acquired pneumonia (CAP), which spreads more easily as people retreat indoors and come into close contact. The lung infection triggers persistent coughing, chest pain, fever, and difficulty breathing, and is particularly hard on the very young and the very old. In fact, pneumonia is the leading cause of hospitalization among U.S. children, with estimated medical costs of $1 billion annually. [More]
Study points respiratory viruses as the most common cause of childhood pneumonia

Study points respiratory viruses as the most common cause of childhood pneumonia

Respiratory viruses, not bacterial infections, are the most commonly detected causes of community-acquired pneumonia in children, according to new research released Feb. 26 in the New England Journal of Medicine. [More]
Using Cultrex BME 2 reduced growth factor to enable long-term culture of human hepatocytes

Using Cultrex BME 2 reduced growth factor to enable long-term culture of human hepatocytes

AMSBIO reports on the recent publication in Cell [1] by Dr Meritxell Huch, Prof Hans Clevers et al. of ground-breaking research using Cultrex BME2 reduced growth factor (organoid growth matrix) to enable long-term (>1 year) culture of genome-stable bipotent stem cells from adult human liver. These results open up new experimental avenues towards the use of human liver material expanded in vitro as an alternative cell source for disease modeling, toxicology studies, drug testing, regenerative medicine and gene therapy. [More]
Efficacy of ebola vaccine to be assessed in large-scale clinical trial

Efficacy of ebola vaccine to be assessed in large-scale clinical trial

GlaxoSmithKline (GSK) announced today that they will soon be commencing the first large-scale clinical trial to assess the efficacy of an experimental ebola vaccine. [More]
NCCS launches human clinical trial of new cancer vaccine

NCCS launches human clinical trial of new cancer vaccine

The National Cancer Centre Singapore has launched a clinical trial of a new cancer vaccine administered to human patients for the first time in the world. Cancer immunotherapy (the harnessing of the body's defence system to fight the patient's cancer, has emerged as one of the most exciting medical breakthroughs in the past two years. [More]
Ultraspecific and extensively validated monoclonal antibodies now available from AMSBIO

Ultraspecific and extensively validated monoclonal antibodies now available from AMSBIO

AMSBIO has announced the availability of ultraspecific and extensively validated monoclonal antibodies under the UltraMAB™ brand. [More]
Antigens and antibodies for an optimised ELISA test kit for Ebola

Antigens and antibodies for an optimised ELISA test kit for Ebola

AMSBIO has announced several products suitable for the development of an ELISA detection assay for the Ebola virus. [More]
Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157

Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157

Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, and ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the companies have entered into a strategic collaboration for the further clinical development and commercialization of CMX157. [More]
AMSBIO announces DNA-In™ Neuro Transfection Reagent

AMSBIO announces DNA-In™ Neuro Transfection Reagent

AMSBIO announces DNA-In™ Neuro- a new generation transfection reagent developed specifically for maximum nucleic acid delivery into neurons, typically achieving a 2-fold or greater improvement in efficiency over currently available competing reagents. [More]
CRISPR/Cas9 genome editing: an interview with Maja Petkovic

CRISPR/Cas9 genome editing: an interview with Maja Petkovic

RNA guided CRISPR nucleases have a great potential for genome modification in many different organisms. [More]
Fenofibrate benefits in diabetic retinopathy mediated through PPARα

Fenofibrate benefits in diabetic retinopathy mediated through PPARα

Peroxisome proliferator–activated receptor α exerts protective effects on retinal pericytes, shows research that explains why fenofibrate is protective against diabetic retinopathy. [More]
Cultrex® Embryoid Body Formation Kit introduced by AMSBIO

Cultrex® Embryoid Body Formation Kit introduced by AMSBIO

AMSBIO, experts in extracellular matrices, have introduced the Cultrex® Embryoid Body Formation Kit to generate consistent, reproducible and identical in size embryoid bodies. It has been qualified to form embryoid bodies from human pluripotent stem cells. Embryoid bodies are finding increasing use in regenerative medicine, in-vitro screening and as a model of embryonic development. [More]
Advertisement
Advertisement